Edition:
United States

Erytech Pharma SA (ERYP.OQ)

ERYP.OQ on NASDAQ Stock Exchange Global Select Market

19.20USD
8 Dec 2017
Change (% chg)

$-8.80 (-31.43%)
Prev Close
$28.00
Open
$20.00
Day's High
$20.26
Day's Low
$19.02
Volume
14,712
Avg. Vol
--
52-wk High
$30.48
52-wk Low
$19.02

Select another date:

Fri, Nov 10 2017

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​

* ‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​

BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​

* ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS

BRIEF-Erytech Pharma 9M net loss widens to 20.8 million euros

* ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO

BRIEF-Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs

* Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing

BRIEF-Erytech Pharma ‍announces resubmission of european marketing authorization application for GRASPA

* ‍ANNOUNCES RESUBMISSION OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA IN ACUTE LYMPHOBLASTIC LEUKEMIA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Erytech Pharma files for U.S. IPO of up to $100 mln of ADSS

* Erytech Pharma Sa files for U.S. IPO of up to $100 million of ADSS - SEC filing‍​

BRIEF-Erytech Pharma H1 net loss widens to ‍​14.0 million euros

* ERYTECH REPORTS FIRST HALF 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​

* COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL ‍​

BRIEF-Erytech announces collaboration with Queen’s University

* ERYTECH ANNOUNCES COLLABORATION WITH QUEEN’S UNIVERSITY TO ADVANCE ITS PRODUCT CANDIDATE FOR RARE METABOLIC DISORDERS

Select another date: